Format
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 4

1.

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY.

J Clin Oncol. 2011 Jul 1;29(19):2689-95. doi: 10.1200/JCO.2010.34.1636. Epub 2011 May 23.

2.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

3.

Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.

Batich KA, Sampson JH.

Expert Opin Pharmacother. 2014 Oct;15(14):2047-61. doi: 10.1517/14656566.2014.947266. Epub 2014 Aug 19. Review.

4.

VEGF Manipulation in Glioblastoma.

Weathers SP, de Groot J.

Oncology (Williston Park). 2015 Oct;29(10):720-7. Review.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk